Amneal Pharmaceuticals, Inc.
AMRX
$11.98
-$0.14-1.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 814.32M | 784.51M | 724.51M | 695.42M | 730.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 814.32M | 784.51M | 724.51M | 695.42M | 730.52M |
| Cost of Revenue | 518.54M | 490.19M | 440.27M | 441.30M | 469.50M |
| Gross Profit | 295.78M | 294.32M | 284.24M | 254.12M | 261.02M |
| SG&A Expenses | 146.48M | 137.82M | 124.27M | 118.29M | 128.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.00K | -117.00K | -- | -5.12M | 0.00 |
| Total Operating Expenses | 699.82M | 691.24M | 612.50M | 594.50M | 652.45M |
| Operating Income | 114.50M | 93.27M | 112.01M | 100.92M | 78.07M |
| Income Before Tax | 55.24M | -5.22M | 51.71M | 37.49M | -15.32M |
| Income Tax Expenses | 5.66M | -23.36M | 16.10M | 12.87M | 5.42M |
| Earnings from Continuing Operations | 49.57M | 18.13M | 35.61M | 24.62M | -20.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -14.50M | -15.76M | -13.19M | -12.42M | -10.34M |
| Net Income | 35.08M | 2.37M | 22.42M | 12.20M | -31.08M |
| EBIT | 114.50M | 93.27M | 112.01M | 100.92M | 78.07M |
| EBITDA | 163.73M | 147.34M | 172.12M | 161.08M | 144.20M |
| EPS Basic | 0.11 | 0.01 | 0.07 | 0.04 | -0.10 |
| Normalized Basic EPS | 0.07 | 0.05 | 0.06 | 0.04 | -0.07 |
| EPS Diluted | 0.11 | 0.01 | 0.07 | 0.04 | -0.10 |
| Normalized Diluted EPS | 0.07 | 0.05 | 0.06 | 0.04 | -0.07 |
| Average Basic Shares Outstanding | 314.46M | 314.17M | 313.74M | 311.05M | 309.85M |
| Average Diluted Shares Outstanding | 328.09M | 324.75M | 322.36M | 323.96M | 309.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |